Incyte Corporation
Wilmington, DE United States
(NASDAQ: INCY)

Company Description

Incyte hopes its success with inhibitors is uninhibited. The biotechnology company is focused on discovering and developing drugs that inhibit specific enzymes associated with cancer, diabetes, blood disorders, and inflammatory diseases. The company's lead program is its JAK (Janus associated kinase) inhibitor program, which covers treatments for inflammatory diseases and cancers. Its first commercial product, JAKAFI for myelofibrosis (a rare blood cancer), was approved by the FDA in 2011. Incyte's other JAK product candidates are in various stages of research and clinical trials, partially through partnerships with other drugmakers, for conditions including rheumatoid arthritis, psoriasis, solid tumors, and breast cancer.

Experimental Station, Route 141 & Henry Clay Road, Bldg. E336	Phone: 302-498-6700	http://www.incyte.com
Wilmington, DE 19880	Fax: 302-425-2750	Map This Company
United States

Try a Full Premium Subscription

Access over 85 million companies
Call (866) 443-3939 or

Incyte Corporation Rankings

Russell 2000 (June 2011)

Executives

24 executives listed for Incyte Corporation's Wilmington, DE location.
Chairman	Richard De Schutter	E-mail
President, CEO and Director	Paul Friedman	E-mail
EVP and CFO	David Hastings	E-mail

More Incyte Corporation Executives

Financials

Company Type	Public - NASDAQ: INCY Headquarters
Fiscal Year-End	December
2011 Employees	368

More Incyte Corporation Financials

DNBi

Leverage D&B's credit assessment tools to positively impact
your business. Get the scoop on Incyte Corporation now.

Reduce risk.
Drive greater profitability.
Increase cash flow.

Incyte CorporationWilmington, DE United States (NASDAQ: INCY)